BONESUPPORT announced the milestone of >20,000 patients treated worldwide with CERAMENT™ injectable drug-eluting bone substitute products.
Company leadership attributes strong adoption to the efforts of its U.S. distribution partner, Zimmer Biomet, and strong surgeon demand in the EU for CERAMENT™|G (gentamicin) and CERAMENT™ V (vancomycin), indicated to promote bone healing in the management of infections.
CERAMENT G has been on the EU market since launch in 1Q13, while CERAMENT V entered EU launch in early 2Q15. The company signed its original distribution agreement with Biomet in 2012.
BONESUPPORT announced the milestone of >20,000 patients treated worldwide with CERAMENT™ injectable drug-eluting bone substitute products.
Company leadership attributes strong adoption to the efforts of its U.S. distribution partner, Zimmer Biomet, and strong surgeon demand in the EU for CERAMENT™|G (gentamicin) and CERAMENT™ V...
BONESUPPORT announced the milestone of >20,000 patients treated worldwide with CERAMENT™ injectable drug-eluting bone substitute products.
Company leadership attributes strong adoption to the efforts of its U.S. distribution partner, Zimmer Biomet, and strong surgeon demand in the EU for CERAMENT™|G (gentamicin) and CERAMENT™ V (vancomycin), indicated to promote bone healing in the management of infections.
CERAMENT G has been on the EU market since launch in 1Q13, while CERAMENT V entered EU launch in early 2Q15. The company signed its original distribution agreement with Biomet in 2012.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Copy to clipboard 
